

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY AGREEMENT

**CONVEYING PARTY DATA**

Name	Execution Date
JPMORGAN CHASE BANK, N.A., TORONTO BRANCH	09/28/2010

**RECEIVING PARTY DATA**

Name:	BIOVAIL CORPORATION
Street Address:	7150 MISSISSAUGA ROAD
City:	MISSISSAUGA, ONTARIO
State/Country:	CANADA
Postal Code:	L5N 8M5

Name:	PRESTWICK PHARMACEUTICALS, INC.
Street Address:	700 ROUTE 202/206NORTH
City:	BRIDGEWATER
State/Country:	NEW JERSEY
Postal Code:	08801

**PROPERTY NUMBERS Total: 4**

Property Type	Number
Patent Number:	7514454
Patent Number:	7488755
Patent Number:	7189742
Application Number:	12382511

**CORRESPONDENCE DATA**

Fax Number: (866)826-5420  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 3016380511  
 Email: ipresearchplus@comcast.net  
 Correspondent Name: IP Research Plus, Inc.

OP \$160.00 7514454

Address Line 1: 21 Tadcaster Circle  
Address Line 2: Attn: Penelope J.A. Agodoa  
Address Line 4: Waldorf, MARYLAND 20602

ATTORNEY DOCKET NUMBER: 36146

NAME OF SUBMITTER: Penelope J.A. Agodoa

Total Attachments: 5  
source=36146#page1.tif  
source=36146#page2.tif  
source=36146#page3.tif  
source=36146#page4.tif  
source=36146#page5.tif

## RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

**1. Name of conveying party(ies)**

JPMORGAN CHASE BANK, N.A., TORONTO BRANCH

Additional name(s) of conveying party(ies) attached?  Yes  No

**2. Name and address of receiving party(ies)**

Name: BIOVAIL CORPORATION

Internal Address: \_\_\_\_\_

Street Address: 7150 MISSISSAUGA ROAD

City: MISSISSAUGA

State: ONTARIO

Country: CANADA

Zip: L5N 8M5

Additional name(s) & address(es) attached?  Yes  No

**3. Nature of conveyance/Execution Date(s):**

Execution Date(s) SEPTEMBER 28, 2010

- |  |   |
|--|---|
| <input type="checkbox"/> Assignment  | <input type="checkbox"/> Merger         |
| <input type="checkbox"/> Security Agreement                                    | <input type="checkbox"/> Change of Name |
| <input type="checkbox"/> Joint Research Agreement                              |   |
| <input type="checkbox"/> Government Interest Assignment                        |   |
| <input type="checkbox"/> Executive Order 9424, Confirmatory License            |   |
| <input checked="" type="checkbox"/> Other <u>RELEASE OF SECURITY AGREEMENT</u> |   |

**4. Application or patent number(s):**

This document is being filed together with a new application.

A. Patent Application No.(s)

PLEASE SEE ATTACHED SCHEDULE.

B. Patent No.(s)

PLEASE SEE ATTACHED SCHEDULE.

Additional numbers attached?  Yes  No

**5. Name and address to whom correspondence concerning document should be mailed:**

Name: IP Research Plus

Internal Address: \_\_\_\_\_

Attn: Penelope J.A. Agodoa

Street Address: \_\_\_\_\_

21 Tadcaster Circle

City: Waldorf

State: MD

Zip: 20602

Phone Number: 301-638-0511

Fax Number: 866-826-5420

Email Address: orders@ipresearchplus.com

**6. Total number of applications and patents involved:** 4**7. Total fee (37 CFR 1.21(h) & 3.41) \$** \_\_\_\_\_

- Authorized to be charged by credit card  
 Authorized to be charged to deposit account  
 Enclosed  
 None required (government interest not affecting title)

**8. Payment Information**


a. Credit Card Last 4 Numbers \_\_\_\_\_

Expiration Date \_\_\_\_\_

b. Deposit Account Number \_\_\_\_\_

Authorized User Name \_\_\_\_\_

**9. Signature:**

  
Signature

OCTOBER 5, 2010

Date

Eric Spierer

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

5

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

**PATENT**  
**REEL: 025095 FRAME: 0638**

Additional Receiving Party:

PRESTWICK PHARMACEUTICALS, INC. - A DELAWARE CORPORATION  
700 ROUTE 202/206 NORTH  
BRIDGEWATER, NEW JERSEY 08801

RELEASE OF PATENT SECURITY INTEREST,  
dated as of September 28, 2010 (this "Release"), by JPMORGAN  
CHASE BANK, N.A., as Administrative Agent (as defined below).  
Capitalized terms used herein and not otherwise defined shall have the  
meanings assigned to such terms in the Credit Agreement and the  
Patent Security Agreement, as applicable, referred to below.

Reference is made to (i) the Credit Agreement, dated as of June 9, 2009 (the "Credit Agreement"), among Biovail Corporation, a corporation continued under the federal laws of Canada, the Lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent ("Administrative Agent") and the other agents party thereto and (ii) the Patent Security Agreement dated as of June 9, 2009 (the "Patent Security Agreement"), between Prestwick Pharmaceuticals, Inc., a Delaware corporation (the "Grantor") and the Administrative Agent for the lenders from time to time party to the Credit Agreement (the lenders collectively, the "Secured Parties").

WHEREAS, pursuant to the Credit Agreement and the Patent Security Agreement, the Grantors granted a security interest to the Administrative Agent, for the benefit of the Secured Parties, in, among other things, the patents of the Grantors set forth on Schedule I hereto (the "Patents"), which security interest was recorded with the United States Patent & Trademark Office (the "USTPO") on June 10, 2009 at 022804/0321.

WHEREAS, in connection with the termination of the Commitments under the Credit Agreement and the payment in full of all of the Loans and other Obligations (other than obligations in respect of any Swap Agreement not due or payable), and the release of security interests under the Loan Documents, the Grantors have informed the Administrative Agent of their desire to obtain the release of all right, title and interest of the Administrative Agent, the Secured Parties and each other grantee or beneficiary in and to the Patents granted under the Patent Security Agreement.

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent does hereby release, cancel, relinquish and discharge any and all security interests it has against the Patents and reassigns all right, title and interest it has in the Patents to the Grantors. The Administrative Agent agrees to make filings with the USPTO and other necessary filings, in each case as reasonably requested by the Grantors and at the expense of the Grantors, to evidence the release and termination of the Administrative Agent's security interests in the Patents. The Administrative Agent shall take all further actions and provide to the Grantors, assigns or other legal representatives all such cooperation and assistance, as reasonably requested by the Grantors and at the expense of the Grantors, to more fully and effectively effectuate the purposes of this Release.

THIS RELEASE SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK AND SHALL BE BINDING UPON THE PARTIES HERETO AND THEIR RESPECTIVE SUCCESSORS AND ASSIGNS.

IN WITNESS WHEREOF, the Administrative Agent has duly executed this Release as of the day and year first above written.

JPMORGAN CHASE BANK, N.A.,  
TORONTO BRANCH, as  
Administrative Agent,

By:  
Robert S. Sheppard  
Name: ROBERT S. SHEPPARD  
Title: VICE PRESIDENT

By:  
\_\_\_\_\_  
Name:  
Title:

Signature Page to the Patent Release

{HYCORP:3259313 v3.4842D-09/25/10-07/20 p}

**PATENT**  
**REEL: 025095 FRAME: 0641**

**Schedule I**

UNITED STATES PATENTS

<u>Name of Grantor</u>	<u>Patent Description</u>	<u>Patent Number</u>	<u>Issue Date</u>
Prestwick Pharmaceuticals, Inc.	Peperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders	7,514,454	April 7, 2009
Prestwick Pharmaceuticals, Inc.	Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid	7,488,755	February 10, 2009
Prestwick Pharmaceuticals, Inc.	Peperidin-2,6-dione bisulphate salts and their use for the treatment of stress related affective disorders	7,189,742	March 13, 2007

UNITED STATES PENDING PATENT APPLICATIONS

<u>Name of Grantor</u>	<u>Patent Description</u>	<u>Patent Application Number</u>	<u>Filing Date</u>
Prestwick Pharmaceuticals, Inc.	Peperidin-2,6-dione bisulphate salts and their use for the treatment of stress related affective disorders	US 12/382,511* <i>* This application is a continuation of US 7,514,454</i>	March 18, 2009